Comparison between pegloticase and pegadricase Phase II: COMPARE trial [27]
| Pegloticase (n = 87) | Pegadricase (n = 83) | |
|---|---|---|
| Origin | Porcine and baboon Uricase | Candida Utilis |
| Treatment regimen | 8 mg every 2 weeks IV | 0.2 mg/kg pegadricase, 0.15 mg/kg ImmTOR monthly IV |
| Immunomodulation | Methotrexate 15 mg PO weekly | Rapamycin |
| Efficacy | Pegadricase did not meet the primary endpoint of statistical superiority SU (serum urate) < 6 mg/dL for at least 80% of the time during months 3 and 6 combined: 59% pegadricase vs 46% pegloticase, P = 0.181Decrease in mean SU levels compared to pegloticase (P = 0.0033) | |
| AEs n (%) | 34 (39.1%) | 45 (54.2%) |
| Gout flare | 20 (23.0%) | 27 (32.5%) |
| infusion-related reaction | 10 (11.5%) | 13 (15.7%) |
| Headache | 0 | 4 (4.8%) |
| Hypertriglyceridemia | 2 (2.3%) | 3 (3.6%) |
| Aphthous ulcer | 0 | 2 (2.4%) |
| Pegylation | yes | yes |
| Half-life (days) | 6–14 | 3 |
